Accessibility Menu

Scribe Therapeutics(NASDAQ) SCTX

Current Price$22.71
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A

Scribe Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.36

Net Income (TTM)

-$20.77

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$22.71

Volume

511,617.607

Open

$25.00

Previous Close

$15.00

Daily Range

$22.06 - $25.49

52-Week Range

$22.06 - $25.49

Estimated Earnings Date

N/A

SCTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scribe Therapeutics

Scribe Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing in vivo CRISPR-based genetic medicines. The company focuses on engineering proprietary technologies to target the genetic drivers of diseases, particularly atherosclerotic cardiovascular disease (ASCVD), with the goal of transitioning treatment from chronic care to preventative intervention.

Products and Services
  • Development of CRISPR-based genetic therapies
  • Focus on atherosclerotic cardiovascular disease treatment
  • Innovative technologies for gene editing and disease prevention
Growth Outlook
  • Potential to revolutionize treatment paradigms in cardiovascular diseases
  • Strong pipeline of CRISPR-based therapies under development
  • Increasing demand for preventative healthcare solutions
Financial Highlights
  • Market capitalization of approximately $387.8 million
  • Stock price range between $23 and $25.25 over the past year
  • Recent trading volume of 317,055 shares
Scribe Therapeutics is positioned at the forefront of genetic medicine, leveraging CRISPR technology to address significant health challenges. The focus on atherosclerotic cardiovascular disease highlights the company's commitment to innovative solutions that could reshape treatment approaches. With a solid market capitalization and a robust pipeline, Scribe Therapeutics presents an intriguing opportunity for investors interested in the biotechnology sector. The company's strategic direction and emphasis on preventative care align with growing trends in healthcare, potentially enhancing its market position in the coming years.
AI Generated • Jul 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

89

CEO

Benjamin L. Oakes, PhD

Website

www.scribetx.com

Headquarters

Alameda, CA 94501, US

SCTX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

511.62K

Avg. Volume

0

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Scribe Therapeutics Performance Analysis

Scribe Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 27,413,000N/A
20252025-12-31USD 51,174,00086.7%
Scribe Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -2.95N/A
20252025-12-31USD -1.35-54.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.23

N/A

Gross Profit

$1.46

N/A

Gross Margin

65.38%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

89

N/A

Net Income

-$17.35

N/A

EBITDA

-$11.65

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$66.71

N/A

Total Debt

$46.33

N/A

Accounts Receivable

$1.28

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.46

N/A

Short Term Debt

$41.87

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$7.57

N/A

Operating Cash Flow

-$7.56

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,399.15-0.01%
^DJIDJI
$51,649.46-0.01%
^IXICNASDAQ
$25,099.92-0.02%
BTCBitcoin
$64,725.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.33-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$65.67-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.69+0.01%
CLFCleveland-Cliffs
$11.71+0.07%

Questions About SCTX

What is the current price of Scribe Therapeutics?

Scribe Therapeutics is trading at $22.71 per share.

What is the 52-week range for Scribe Therapeutics?

Over the past 52 weeks, Scribe Therapeutics has traded between $22.06 and $25.49.

How much debt does Scribe Therapeutics have?

As of the most recent reporting period, Scribe Therapeutics reported total debt of $46.33M.

How much cash does Scribe Therapeutics have on hand?

Scribe Therapeutics reported $20.38M in cash and cash equivalents in its most recent financial results.

What is Scribe Therapeutics’s dividend yield?

Scribe Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services